Benign Hematology | Maryland Oncology Hematology Benign Hematology – Maryland Oncology Hematology

Trial ID 21367

NCT05155605 ID
USOR ID: 21367
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

Trial ID 21473

NCT05171049 ID
USOR ID: 21473 Phase III
ASTER: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology